BlackRock
MBX

BlackRock’s MBX Biosciences MBX Stock Holding History

BlackRock’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$183M Buy
3,323,672
+382,266
+13% +$13.4M ﹤0.01% 1848
2026
Q1 		$87.8M Buy
2,941,406
+21,650
+0.7% +$736K ﹤0.01% 2180
2025
Q4 		$92.1M Buy
2,919,756
+962,295
+49% +$23.3M ﹤0.01% 2155
2025
Q3 		$34.3M Buy
1,957,461
+945,915
+94% +$12.6M ﹤0.01% 2749
2025
Q2 		$11.5M Buy
1,011,546
+228,504
+29% +$2.33M ﹤0.01% 3341
2025
Q1 		$5.78M Buy
783,042
+55,090
+8% +$582K ﹤0.01% 3589
2024
Q4 		$13.4M Buy
+727,952
New +$15.5M ﹤0.01% 3267

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock's MBX Position: Q2 2026 in Review

BlackRock increased its MBX Biosciences (MBX) stake by 13% in Q2 2026, buying an estimated $13.4M and bringing the position to 3,323,672 shares worth $183M. The position accounts for ﹤0.01% of the portfolio, ranked #1848.

BlackRock first reported a position in MBX in Q4 2024 and has held it in 7 quarters since. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • BlackRock held 3,323,672 shares of MBX Biosciences worth $183M as of Q2 2026.
  • BlackRock bought 382,266 MBX Biosciences shares in Q2 2026, an estimated $13.4M.
  • MBX Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1848 holding.
  • BlackRock first reported a position in MBX Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.